The entire pharma pack has been quite attractive for some time now. Now, Gilead, the patent holder for Remdesivir, has licensed five companies in the emerging markets to manufacture the generic version of the tablets for distribution till COVID-19 cases are rampant across the world. The Indian companies that secured the license from Gilead included Hetero Drugs, Cipla and Jubilant Life Sciences. In addition, Gilead also licensed this patent to a Pakistan based pharma company and also to US based Mylan; with substantial operations in India. There will be no patent fees payable for the formula since it is being manufactured for the specific purpose of addressing the COVID-19 pandemic. It could be a sentiment booster for these pharma stocks as it opens up a huge window for them.